ASCO-GI 2021: KEYNOTE 240 Update Supports Second-Line Pembrolizumab Therapy in Advanced Hepatocellular Carcinoma
Second interim results demonstrate both overall and progression-free survival benefits
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.